Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Erwin Gelfand

Pediatrics Denver, CO Medical Doctor

NPI 1164503405 CMS profile 652761

1400 Jackson St, Denver, CO 80206

Open in the dashboard

General payments

$143,144

133 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$34,606 paid to institutions, not to them · program year 2020

Through program year 2024, Erwin Gelfand of Denver, CO is reported in the CMS Open Payments database as having received $143,144 across 133 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $34,606 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $532 1
2023 General $8,500 1
2021 General $7,521 5
2020 General $32,258 20
2019 General $94,333 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erwin Gelfand
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Erwin Gelfand were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Erwin Gelfand Pediatrics median Middle half National median
2019 $94,333 $86 $31–$183 $163
2020 $32,258 $49 $22–$110 $114
2021 $7,521 $68 $27–$158 $132
2022 $0 $77 $30–$173 $149
2023 $8,500 $88 $33–$190 $160
2024 $532 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Alexion Pharmaceuticals, Inc. $100,716 122 payments
  2. ADMA BioManufacturing LLC $29,225 3 payments
  3. Siemens Medical Solutions USA, Inc. $8,500 1 payment
  4. Spark Therapeutics, Inc. $4,101 5 payments
  5. TerSera Therapeutics LLC $532 1 payment
  6. Grifols Shared Services North America, Inc. $70 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84,360 27 payments
  2. Consulting Fee $46,248 14 payments
  3. Travel and Lodging $10,602 51 payments
  4. Food and Beverage $1,934 41 payments
Products named General payments · program years 2019–2024
  1. Soliris $14,784 12 payments
  2. Gamunex-C $70 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record